

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

Accounting Title	2020/03/31	2019/12/31	2019/03/31
<b>Balance Sheet</b>			
<b>Current assets</b>			
Cash and cash equivalents	377,089	193,671	580,373
Current financial assets at amortised cost	9,710	84,760	39,082
Current contract assets	69,200	22,667	24,872
Accounts receivable, net	39,452	93,111	49,069
Accounts receivable due from related parties, net	3,193	10,602	1,554
Other receivables	7,685	1,829	11,784
Current inventories	58,496	56,123	59,391
Prepayments	21,434	24,242	27,925
Other current assets	2,783	7,954	14,434
<b>Total current assets</b>	<b>589,042</b>	<b>494,959</b>	<b>808,484</b>
<b>Non-current assets</b>			
Non-current financial assets at fair value through other comprehensive income	109,461	149,305	121,879
Property, plant and equipment	534,068	545,077	571,578
Right-of-use assets	48,730	47,762	46,931
Intangible assets	70,787	74,850	86,424
Deferred tax assets	80,736	79,710	72,916
Other non-current assets	23,903	16,331	5,094
<b>Total non-current assets</b>	<b>867,685</b>	<b>913,035</b>	<b>904,822</b>
<b>Total assets</b>	<b>1,456,727</b>	<b>1,407,994</b>	<b>1,713,306</b>
<b>Current liabilities</b>			
Current borrowings	100,000	0	0
Current contract liabilities	138,016	91,686	73,989
Accounts payable	28,674	24,699	23,194
Other payables	58,659	87,979	57,578
Other payables to related parties	292	13,328	131,000
Current lease liabilities	14,142	13,623	10,731
Other current liabilities	820	600	9,251
<b>Total current liabilities</b>	<b>340,603</b>	<b>231,915</b>	<b>305,743</b>
<b>Non-current liabilities</b>			
Non-current portion of non-current borrowings	0	0	98,879
Deferred tax liabilities	512	3,806	2,985
Non-current lease liabilities	33,701	33,177	36,308
Other non-current liabilities	37,375	37,143	30,041
<b>Total non-current liabilities</b>	<b>71,588</b>	<b>74,126</b>	<b>168,213</b>
<b>Total liabilities</b>	<b>412,191</b>	<b>306,041</b>	<b>473,956</b>
<b>Share capital</b>			
Ordinary share	1,279,545	1,279,545	1,279,545
<b>Total share capital</b>	<b>1,279,545</b>	<b>1,279,545</b>	<b>1,279,545</b>
<b>Capital surplus</b>			
Capital surplus, additional paid-in capital	221,400	221,400	482,901
Capital surplus, employee share options	39,690	39,508	39,363
<b>Total capital surplus</b>	<b>261,090</b>	<b>260,908</b>	<b>522,264</b>
<b>Retained earnings</b>			
Unappropriated retained earnings (accumulated deficit)	-494,914	-473,311	-571,857
<b>Total retained earnings</b>	<b>-494,914</b>	<b>-473,311</b>	<b>-571,857</b>
<b>Other equity interest</b>			
Unrealised gains (losses) from financial assets measured at fair value through other comprehensive income	-1,185	34,811	9,398
<b>Total other equity interest</b>	<b>-1,185</b>	<b>34,811</b>	<b>9,398</b>
Treasury shares	0	0	0
<b>Total equity</b>	<b>1,044,536</b>	<b>1,101,953</b>	<b>1,239,350</b>
<b>Total liabilities and equity</b>	<b>1,456,727</b>	<b>1,407,994</b>	<b>1,713,306</b>
Number of share capital awaiting retirement	0	0	0
Equivalent issue shares of advance receipts for ordinary share	0	0	0
Number of shares in entity held by entity and by its subsidiaries	0	0	0

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

Accounting Title	2020/01/01To2020/03/31	2019/01/01To2019/03/31
<b>Income Statement</b>		
Total operating revenue	69,861	66,382
Total operating costs	61,917	43,110
Gross profit (loss) from operations	7,944	23,272
Gross profit (loss) from operations	7,944	23,272
Operating expenses		
Selling expenses	8,764	3,448
Administrative expenses	9,808	8,149
Research and development expenses	14,971	69,872
Impairment loss (impairment gain and reversal of impairment loss) determined in accordance with IFRS 9	324	1,060
Total operating expenses	33,867	82,529
Net operating income (loss)	-25,923	-59,257
Non-operating income and expenses		
Total other income	1,592	3,413
Other gains and losses, net	2,809	1,102
Finance costs, net	563	466
Total non-operating income and expenses	3,838	4,049
Profit (loss) from continuing operations before tax	-22,085	-55,208
Total tax expense (income)	-482	-3,048
Profit (loss) from continuing operations	-21,603	-52,160
Profit (loss)	-21,603	-52,160
Other comprehensive income		
Unrealised gains (losses) from investments in equity instruments measured at fair value through other comprehensive income	-39,844	-15,702
Income tax related to components of other comprehensive income that will not be reclassified to profit or loss	-3,848	1,281
Components of other comprehensive income that will not be reclassified to profit or loss	-35,996	-16,983
Other comprehensive income, net	-35,996	-16,983
Total comprehensive income	-57,599	-69,143
Basic earnings per share		
Total basic earnings per share	-0.17	-0.44

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

Accounting Title	2020/01/01To2020/03/31	2019/01/01To2019/03/31
<b>Statements of Cash Flows</b>		
Cash flows from (used in) operating activities, indirect method		
Profit (loss) from continuing operations before tax	-22,085	-55,208
Profit (loss) before tax	-22,085	-55,208
Depreciation expense	27,745	25,190
Amortization expense	4,063	1,851
Expected credit loss (gain) / Provision (reversal of provision) for bad debt expense	324	1,060
Interest expense	563	466
Interest income	-602	-281
Share-based payments	182	78
Impairment loss on non-financial assets	326	704
Other adjustments to reconcile profit (loss)	-5	0
Total adjustments to reconcile profit (loss)	32,596	29,068
Decrease (increase) in contract assets	-46,533	-9,542
Decrease (increase) in accounts receivable	53,292	3,959
Decrease (increase) in accounts receivable due from related parties	7,451	-1,262
Decrease (increase) in other receivable	-5,717	-2,082
Decrease (increase) in inventories	-2,699	322
Decrease (increase) in prepayments	2,808	-5,089
Decrease (increase) in other current assets	5,221	-1,967
Total changes in operating assets	13,823	-15,661
Increase (decrease) in contract liabilities	46,330	25,472
Increase (decrease) in accounts payable	3,975	-16,693
Increase (decrease) in other payable	-21,299	-32,710
Increase (decrease) in other payable to related parties	64	-19
Increase (decrease) in other current liabilities	220	496
Increase (decrease) in net defined benefit liability	-10	-21
Total changes in operating liabilities	29,280	-23,475
Total changes in operating assets and liabilities	43,103	-39,136
Total adjustments	75,699	-10,068
Cash inflow (outflow) generated from operations	53,614	-65,276
Interest paid	-242	-390
Income taxes refund (paid)	-40	-491
Net cash flows from (used in) operating activities	53,332	-66,157
Cash flows from (used in) investing activities		
Proceeds from disposal of financial assets at amortised cost	75,050	49,517
Acquisition of property, plant and equipment	-18,014	-124,204
Increase in refundable deposits	330	5
Acquisition of intangible assets	0	-46
Increase in prepayments for business facilities	-10,742	-812
Interest received	464	350
Other investing activities	-13,100	0
Net cash flows from (used in) investing activities	33,988	-75,190
Cash flows from (used in) financing activities		
Increase in short-term loans	100,000	0
Proceeds from long-term debt	0	107,298
Payments of lease liabilities	-3,902	-2,723
Proceeds from issuing shares	0	401,400
Net cash flows from (used in) financing activities	96,098	505,975
Effect of exchange rate changes on cash and cash equivalents	0	0
Net increase (decrease) in cash and cash equivalents	183,418	364,628
Cash and cash equivalents at beginning of period	193,671	215,745
Cash and cash equivalents at end of period	377,089	580,373
Cash and cash equivalents reported in the statement of financial position	377,089	580,373
Other items qualifying for cash and cash equivalents under the definition of IAS 7	0	0

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

**2020/03/31 Statement of Stockholders' Equity**

Unit: NT\$ thousand

Accounting Title	Ordinary share	Total share capital	Capital surplus	Unappropriated retained earnings (accumulated deficit)	Total retained earnings	Unrealised gains (losses) on financial assets measured at fair value through other comprehensive income	Total other equity interest	Treasury shares	Total equity
Equity at beginning of period	1,279,545	1,279,545	260,908	-473,311	-473,311	34,811	34,811		1,101,953
Profit (loss)	0	0	0	-21,603	-21,603	0	0		-21,603
Other comprehensive income	0	0	0	0	0	-35,996	-35,996		-35,996
Total comprehensive income	0	0	0	-21,603	-21,603	-35,996	-35,996		-57,599
Share-based payments	0	0	182	0	0	0	0		182
Total increase (decrease) in equity	0	0	182	-21,603	-21,603	-35,996	-35,996		-57,417
Equity at end of period	1,279,545	1,279,545	261,090	-494,914	-494,914	-1,185	-1,185		1,044,536

**2019/03/31 Statement of Stockholders' Equity**

Unit: NT\$ thousand

Accounting Title	Ordinary share	Total share capital	Capital surplus	Unappropriated retained earnings (accumulated deficit)	Total retained earnings	Unrealised gains (losses) on financial assets measured at fair value through other comprehensive income	Total other equity interest	Treasury shares	Total equity
Equity at beginning of period	1,099,545	1,099,545	300,786	-519,697	-519,697	26,381	26,381		907,015
Profit (loss)	0	0	0	-52,160	-52,160	0	0		-52,160
Other comprehensive income	0	0	0	0	0	-16,983	-16,983		-16,983
Total comprehensive income	0	0	0	-52,160	-52,160	-16,983	-16,983		-69,143
Issue of shares	180,000	180,000	221,400	0	0	0	0		401,400
Share-based payments	0	0	78	0	0	0	0		78
Total increase (decrease) in equity	180,000	180,000	221,478	-52,160	-52,160	-16,983	-16,983		332,335
Equity at end of period	1,279,545	1,279,545	522,264	-571,857	-571,857	9,398	9,398		1,239,350